MAPS (Multidisciplinary Association for Psychedelic Studies)

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a nonprofit research and educational organization headquartered in San Jose, California, dedicated to developing psychedelic compounds as prescription medicines. Through its public benefit corporation subsidiary, MAPS PBC, the organization has pioneered the clinical development of MDMA-assisted therapy, a structured treatment protocol that combines the administration of MDMA with intensive psychotherapeutic support. The core therapeutic model integrates pharmacological intervention with evidence-based psychotherapy to address treatment-resistant conditions, most notably post-traumatic stress disorder. This approach represents a departure from traditional psychiatric drug development by treating the medicine and the therapeutic context as inseparable components of the treatment.

MAPS has emerged as the foremost driver of psychedelic medicine's path toward regulatory legitimacy, having successfully advanced MDMA-assisted therapy through Phase 3 clinical trials, the most rigorous stage of the drug approval process. The organization's landmark trials demonstrated statistically significant reductions in PTSD symptom severity, with a substantial proportion of participants no longer meeting diagnostic criteria for the disorder following treatment. These results positioned MAPS PBC at the center of a regulatory review process with the U.S. Food and Drug Administration and international health authorities, marking the first time a psychedelic-assisted therapy had reached this stage of evaluation globally. Their clinical work has effectively established the methodological framework that other psychedelic medicine developers now reference and follow.

MAPS holds considerable strategic importance to the broader neurotechnology and neurotherapeutics industry as the organization that normalized psychedelic compounds within rigorous scientific and regulatory frameworks. By demonstrating that controlled psychedelic experiences could be studied, standardized, and evaluated under FDA oversight, MAPS has opened a credible pathway for an entirely new class of neurological and psychiatric interventions. Their work has catalyzed significant venture capital investment, academic research, and pharmaceutical interest across the psychedelics sector, effectively creating the commercial and scientific ecosystem that now surrounds the space. For the neurotech industry, MAPS represents proof of concept that the brain's response to psychedelic compounds can be harnessed within a translatable, scalable, and regulatorily viable therapeutic model.